PEX010, a psilocybin formulation for potential treatment of MDD

Filament Heath are planning to conducting a Phase II clinical trial exploring the safety and efficacy of using PEX010 to treat major depressive disorder (MDD) while employing a novel control condition.

PEX010 is a naturally sourced psilocybin formulation that has been developed by Filament Health through its drug development subsidiary Psilo Scientific.

Filament has anticipated that FDA approval will be granted in Q4 2021 with the trial set to begin in 2022.

Compound Psilocybin
Country Canada
Visit trial
Status Planned
Results Published
Start date 01 January 2022
End date 01 January 2023
Chance of happening 60%
Phase Phase II
Design Open
Type Interventional
Generation Second
Participants 50
Sex All
Age 18- 99
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

Filament Health
Filament Health is a global extraction and drug discovery company. The company have a deep natural psychedelics IP portfolio and are led by an accomplished botanical extraction management team.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.